A recombinant Mycobacterium smegmatis-based surface display system for developing the T cell-based COVID-19 vaccine

References

• Randolph HE, Barreiro LB. Herd Immunity: understanding COVID-19. Immunity. 2020;52:737–12. doi:10.1016/j.immuni.2020.04.012.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants – clinical, public health, and vaccine implications. N Engl J Med. 2021;384:1866–68. doi:10.1056/NEJMc2100362.
   PubMed Web of Science ®Google Scholar
• Hajnik RL, Plante JA, Liang Y, Alameh MG, Tang J, Bonam SR, Zhong C, Adam A, Scharton D, Rafael GH. Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. Sci Transl Med 2022;14:eabq1945. doi:10.1126/scitranslmed.abq1945.
   PubMed Web of Science ®Google Scholar
• Naranbhai V, Nathan A, Kaseke C, Berrios C, Khatri A, Choi S, Getz MA, Tano-Menka R, Ofoman O, Gayton A, et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell. 2022;185:1041–51. doi:10.1016/j.cell.2022.01.029.
   PubMed Web of Science ®Google Scholar
• Kumar NP, Padmapriyadarsini C, Rajamanickam A, Bhavani PK, Nancy A, Jayadeepa B, Selvaraj N, Asokan D, Renji RM, Venkataramani V, et al. BCG vaccination induces enhanced frequencies of memory T cells and altered plasma levels of common γc cytokines in elderly individuals. PLoS One. 2021;16(11):e0258743. doi:10.1371/journal.pone.0258743.
   PubMed Web of Science ®Google Scholar
• Singhania A, Dubelko P, Kuan R, Chronister WD, Muskat K, Das J, Phillips EJ, Mallal SA, Seumois G, Vijayanand P, et al. CD4+CCR6+ T cells dominate the BCG-induced transcriptional signature. EBioMedicine. 2021;74:103746. doi:10.1016/j.ebiom.2021.103746.
   PubMed Web of Science ®Google Scholar
• Zhu YD, Fennelly G, Miller C, Tarara R, Saxe I, Bloom B, McChesney M. Recombinant bacille Calmette-Guérin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia. J Infect Dis. 1997;176:1445–53. doi:10.1086/514140.
   PubMed Web of Science ®Google Scholar
• Nurul AA, Norazmi MN. Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum. Parasitol Res. 2011;108:887–97. doi:10.1007/s00436-010-2130-5.
   PubMed Web of Science ®Google Scholar
• Jeong H, Lee SY, Seo H, Kim BJ. Recombinant Mycobacterium smegmatis delivering a fusion protein of human macrophage migration inhibitory factor (MIF) and IL-7 exerts an anticancer effect by inducing an immune response against MIF in a tumor-bearing mouse model. J Immunother Cancer. 2021;9(8):e003180. doi:10.1136/jitc-2021-003180.
   PubMed Web of Science ®Google Scholar
• Soto JA, Díaz FE, Retamal-Díaz A, Gálvez NMS, Melo-González F, Piña-Iturbe A, Ramírez MA, Bohmwald K, González PA, Bueno SM, et al. BCG-based vaccines elicit antigen-specific adaptive and trained immunity against SARS-CoV-2 and Andes orthohantavirus. Vaccines (Basel). 2022;10(5):721. doi:10.3390/vaccines10050721.
   PubMed Web of Science ®Google Scholar
• Shiloh MU, Champion PA. To catch a killer. What can mycobacterial models teach us about Mycobacterium tuberculosis pathogenesis? Curr Opin Microbiol. 2010;13(1):86–92. doi:10.1016/j.mib.2009.11.006.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Gong JR, Kim GN, Kim BR, Lee SY, Kook YH, Kim BJ. Recombinant Mycobacterium smegmatis with a pMyong2 vector expressing human immunodeficiency virus Type I Gag can induce enhanced virus-specific immune responses. Sci Rep. 2017;7:44776. doi:10.1038/srep44776.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Kim BR, Kook YH, Kim BJ. Development of a live recombinant BCG expressing human immunodeficiency virus Type 1 (HIV-1) gag using a pMyong2 vector system: potential use as a novel HIV-1 vaccine. Front Immunol. 2018;9:643. doi:10.3389/fimmu.2018.00643.
   PubMed Web of Science ®Google Scholar
• Cayabyab MJ, Hovav AH, Hsu T, Krivulka GR, Lifton MA, Gorgone DA, Fennelly GJ, Haynes BF, Jacobs WR, Letvin NL. Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol. 2006;80(4):1645–52. doi:10.1128/JVI.80.4.1645-1652.2006.
   PubMed Web of Science ®Google Scholar
• Kuehnel MP, Goethe R, Habermann A, Mueller E, Rohde M, Griffiths G, Valentin-Weigand P. Characterization of the intracellular survival of Mycobacterium avium ssp. paratuberculosis: phagosomal pH and fusogenicity in J774 macrophages compared with other mycobacteria. Cell Microbiol. 2001;3(8):551–66. doi:10.1046/j.1462-5822.2001.00139.x.
   PubMed Web of Science ®Google Scholar
• Sweeney KA, Dao DN, Goldberg MF, Hsu T, Venkataswamy MM, Henao-Tamayo M, Ordway D, Sellers RS, Jain P, Chen B, et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med. 2011;17(10):1261–68. doi:10.1038/nm.2420.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80. doi:10.1016/j.cell.2020.02.052.
   PubMed Web of Science ®Google Scholar
• Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369(6505):806–11. doi:10.1126/science.abc6284.
   PubMed Web of Science ®Google Scholar
• Zhao H, Wang TC, Li XF, Zhang NN, Li L, Zhou C, Deng YQ, Cao TS, Yang G, Li RT, et al. Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates. Signal Transduct Target Ther. 2021;6:438. doi:10.1038/s41392-021-00861-4.
   PubMed Web of Science ®Google Scholar
• Harris PE, Brasel T, Massey C, Herst CV, Burkholz S, Lloyd P, Blankenberg T, Bey TM, Carback R, Hodge T, Ciotlos S, Wang L, Comer JE, Rubsamen RM. A synthetic peptide CTL vaccine targeting nucleocapsid confers protection from SARS-CoV-2 challenge in Rhesus Macaques. Vaccines (Basel). 2021;9(5):520. doi:10.3390/vaccines9050520.
   Web of Science ®Google Scholar
• Matchett WE, Joag V, Stolley JM, Shepherd FK, Quarnstrom CF, Mickelson CK, Wijeyesinghe S, Soerens AG, Becker S, Thiede JM, et al. Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. J Immunol. 2021;207(2):376–79. doi:10.4049/jimmunol.2100421.
   PubMed Web of Science ®Google Scholar
• Yang F, Tan Y, Liu J, Liu T, Wang B, Cao Y, Qu Y, Lithgow T, Tan S, Zhang T. Efficient construction of unmarked recombinant mycobacteria using an improved system. J Microbiol Methods. 2014;103:29–36. doi:10.1016/j.mimet.2014.05.007.
   PubMed Web of Science ®Google Scholar
• Goude R, Roberts DM, Parish T. Electroporation of mycobacteria. Methods Mol Biol. 2015;1285:117–30. doi:10.1007/978-1-4939-2450-9_7.
   PubMedGoogle Scholar
• Rezwan M, Laneelle M-A, Sander P, Daffe M. Breaking down the wall: fractionation of mycobacteria. J Microbiol Methods. 2007;68(1):32–39. doi:10.1016/j.mimet.2006.05.016.
   PubMed Web of Science ®Google Scholar
• Li M, Chen J, Liu Y, Zhao J, Li Y, Hu Y, Chen Y-Q, Sun L, Shu Y, Feng F, et al. Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants. Antiviral Res. 2022;205:105383. doi:10.1016/j.antiviral.2022.105383.
   PubMed Web of Science ®Google Scholar
• Wu T, Ma F, Ma X, Jia W, Pan E, Cheng G, Chen L, Sun C. Regulating innate and adaptive immunity for controlling SIV infection by 25-hydroxycholesterol. Front Immunol. 2018;9:2686. doi:10.3389/fimmu.2018.02686.
   PubMed Web of Science ®Google Scholar
• Sun C, Feng L, Zhang Y, Xiao L, Pan W, Li C, Zhang L, Chen L. Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques. J Virol. 2012;86(20):11031–42. doi:10.1128/JVI.00783-12.
   PubMed Web of Science ®Google Scholar
• Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMhcpan-4.0: improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199(9):3360–68. doi:10.4049/jimmunol.1700893.
   PubMed Web of Science ®Google Scholar
• Li M, Yuan Y, Li P, Deng Z, Wen Z, Wang H, Feng F, Zou H, Chen L, Tang S, et al. Comparison of the immunogenicity of HIV-1 CRF07_BC gag antigen with or without a seven amino acid deletion in p6 region. Front Immunol. 2022;13:850719. doi:10.3389/fimmu.2022.850719.
   PubMed Web of Science ®Google Scholar
• Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, Dejnirattisai W, Rostron T, Supasa P, Liu C, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020;21(11):1336–45. doi:10.1038/s41590-020-0782-6.
   PubMed Web of Science ®Google Scholar
• You M, Chen L, Zhang D, Zhao P, Chen Z, Qin E-Q, Gao Y, Davis MM, Yang P. Single-cell epigenomic landscape of peripheral immune cells reveals establishment of trained immunity in individuals convalescing from COVID-19. Nat Cell Biol. 2021;23(6):620–30. doi:10.1038/s41556-021-00690-1.
   PubMed Web of Science ®Google Scholar
• Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin J-B, Olsson A, Llewellyn-Lacey S, Kamal H, Bogdanovic G, Muschiol S, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158–68. doi:10.1016/j.cell.2020.08.017.
   PubMed Web of Science ®Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–501. doi:10.1016/j.cell.2020.05.015.
   PubMed Web of Science ®Google Scholar
• Li M, Zeng J, Li R, Wen Z, Cai Y, Wallin J, Shu Y, Du X, Sun C. Rational design of a pan-coronavirus vaccine based on conserved CTL epitopes. Viruses. 2021;13(2):333. doi:10.3390/v13020333.
   PubMed Web of Science ®Google Scholar
• Tarke A, Sidney J, Kidd CK, Dan JM, Ramirez SI, Yu ED, Mateus J, da Silva Antunes R, Moore E, Rubiro P, et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med. 2021;2(2):100204. doi:10.1016/j.xcrm.2021.100204.
   PubMedGoogle Scholar
• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med. 2020;383(20):1920–31. doi:10.1056/NEJMoa2022483.
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdox1 nCov-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–91. doi:10.1016/S0140-6736(21)00432-3.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81. doi:10.1016/S0140-6736(21)00234-8.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–60. doi:10.1001/jama.2020.15543.
   PubMed Web of Science ®Google Scholar
• Chege GK, Burgers WA, Stutz H, Meyers AE, Chapman R, Kiravu A, Bunjun R, Shephard EG, Jacobs WR, Rybicki EP, et al. Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. J Virol. 2013;87(9):5151–60. doi:10.1128/JVI.03178-12.
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, O’Donnell D, Selby PJ, Jackson AM. Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun. 2005;73(2):784–94. doi:10.1128/IAI.73.2.784-794.2005.
   PubMed Web of Science ®Google Scholar
• Netea MG, Giamarellos-Bourboulis EJ, Domínguez-Andrés J, Curtis N, van Crevel R, van de Veerdonk FL, Bonten M. Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell. 2020;181(5):969–77. doi:10.1016/j.cell.2020.04.042.
   PubMed Web of Science ®Google Scholar
• Rivas MN, Ebinger JE, Wu M, Sun N, Braun J, Sobhani K, Van Eyk JE, Cheng S, Arditi M. BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers. J Clin Invest. 2021;131(2):131. doi:10.1172/JCI145157.
   Web of Science ®Google Scholar
• Zhang B-Z, Shuai H, Gong H-R, Hu J-C, Yan B, Yuen TT, Hu Y-F, Yoon C, Wang X-L, Hou Y, et al. Bacillus Calmette-Guérin–induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice. JCI Insight. 2022;7(11). doi:10.1172/jci.insight.157393.
   Web of Science ®Google Scholar
• Urbán S, Paragi G, Burián K, McLean GR, Virok DP. Identification of similar epitopes between severe acute respiratory syndrome coronavirus-2 and Bacillus Calmette–Guérin: potential for cross-reactive adaptive immunity. Clin Transl Immunol. 2020;9(12):e1227. doi:10.1002/cti2.1227.
   PubMed Web of Science ®Google Scholar
• Hovav A-H, Cayabyab MJ, Panas MW, Santra S, Greenland J, Geiben R, Haynes BF, Jacobs WR, Letvin NL. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis. J Virol. 2007;81(1):74–83. doi:10.1128/JVI.01269-06.
   PubMed Web of Science ®Google Scholar